Everett Moiseff

Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension. RTN-001 has been evaluated in over 265 subjects across 9 clinical trials. In these studies, RTN-001 was well tolerated and demonstrated a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension. RTN-001 is a second generation PDE5i that preferentially distributes to cardiovascular tissues, where it acts to mediate a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension.

The fight against cancer needs new, big, bold ideas. At Siren, we’ve got one: Universal AAV Immuno-Gene Therapy. We are combining two transformative therapeutic technologies – AAV gene therapy and cytokine immunotherapy - into a single, reimagined modality that overcomes key challenges and redefines how we destroy tumor cells and elicit anti-tumor immunity.

Mwamba is a gold mining company dedicated to the acquisition, development, and operation of both early and late-stage resource properties in Tanzania. Mwamba is revolutionizing the gold mining industry with a more sustainable and inclusive model that seeks to partner with and invest in the unmet needs of local Artisanal and Small-scale Gold Mining (ASGM) communities. By providing the necessary resources and guidance, Mwamba helps these communities to safely scale their operations and achieve a better quality of life. Many ASGM miners today lack access to advanced machinery and technology, relying instead on traditional, manual methods that are both inefficient and hazardous. Shafts are often dug by hand, and mercury is commonly used to extract gold from ore—a toxic process that not only endangers human health and the environment but also leaves much of the gold unrecovered. Mwambas ASGM interventions harness modern technologies and industry expertise to help partner miners safely maximize the full potential of their projects. Mines are engineered according to their unique characteristics, and all gold produced is processed in mercury-free, state-of-the-art facilities. Mwamba is globally recognized as a pioneer in sustainable mining reform and is a member of the UNEPs Global Mercury Partnership. The company also serves as a private sector advisor to the GEF-funded, UNEP-led planetGOLD Program.

Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension. RTN-001 has been evaluated in over 265 subjects across 9 clinical trials. In these studies, RTN-001 was well tolerated and demonstrated a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension. RTN-001 is a second generation PDE5i that preferentially distributes to cardiovascular tissues, where it acts to mediate a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension.

The fight against cancer needs new, big, bold ideas. At Siren, we’ve got one: Universal AAV Immuno-Gene Therapy. We are combining two transformative therapeutic technologies – AAV gene therapy and cytokine immunotherapy - into a single, reimagined modality that overcomes key challenges and redefines how we destroy tumor cells and elicit anti-tumor immunity.

Zymergen is now a part of Ginkgo Bioworks!

Mwamba is a gold mining company dedicated to the acquisition, development, and operation of both early and late-stage resource properties in Tanzania. Mwamba is revolutionizing the gold mining industry with a more sustainable and inclusive model that seeks to partner with and invest in the unmet needs of local Artisanal and Small-scale Gold Mining (ASGM) communities. By providing the necessary resources and guidance, Mwamba helps these communities to safely scale their operations and achieve a better quality of life. Many ASGM miners today lack access to advanced machinery and technology, relying instead on traditional, manual methods that are both inefficient and hazardous. Shafts are often dug by hand, and mercury is commonly used to extract gold from ore—a toxic process that not only endangers human health and the environment but also leaves much of the gold unrecovered. Mwambas ASGM interventions harness modern technologies and industry expertise to help partner miners safely maximize the full potential of their projects. Mines are engineered according to their unique characteristics, and all gold produced is processed in mercury-free, state-of-the-art facilities. Mwamba is globally recognized as a pioneer in sustainable mining reform and is a member of the UNEPs Global Mercury Partnership. The company also serves as a private sector advisor to the GEF-funded, UNEP-led planetGOLD Program.